Episurf: Strong long-term data - DNB
The company today announced strong long-term follow-up data from the initial Episealer trial done in Sweden.
We previously saw 24-month data; the patients have now been followed for 75 months and the
data still looks excellent. This is important for Episurf Medical, as many doctors as well as payers request long-term follow-up for the implant system to be included in treatment algorithms and reimbursement systems.
We reiterate our fair value of SEK1.3–3.9
https://www.dnb.no/seg-fundamental/fundamentalweb/GetReportSpon.aspx?file=CMPSP_162171.pdf
Research feed